| Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children A Drilon, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri, ... New England Journal of Medicine 378 (8), 731-739, 2018 | 2620 | 2018 |
| Crizotinib in ROS1-rearranged non–small-cell lung cancer AT Shaw, SHI Ou, YJ Bang, DR Camidge, BJ Solomon, R Salgia, GJ Riely, ... New England Journal of Medicine 371 (21), 1963-1971, 2014 | 2203 | 2014 |
| Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, ... The Lancet Oncology 21 (2), 271-282, 2020 | 1498 | 2020 |
| Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non–small cell lung cancer RC Doebele, AB Pilling, DL Aisner, TG Kutateladze, AT Le, AJ Weickhardt, ... Clinical cancer research 18 (5), 1472-1482, 2012 | 1294 | 2012 |
| Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology DS Ettinger, DE Wood, DL Aisner, W Akerley, J Bauman, LR Chirieac, ... Journal of the National Comprehensive Cancer Network 15 (4), 504-535, 2017 | 1225 | 2017 |
| Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ... The lancet oncology 12 (11), 1004-1012, 2011 | 1146 | 2011 |
| Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional … DR Gomez, C Tang, J Zhang, GR Blumenschein Jr, M Hernandez, JJ Lee, ... Journal of Clinical Oncology 37 (18), 1558-1565, 2019 | 1099 | 2019 |
| Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic … DR Gomez, GR Blumenschein, JJ Lee, M Hernandez, R Ye, DR Camidge, ... The lancet oncology 17 (12), 1672-1682, 2016 | 1061 | 2016 |
| Rociletinib in EGFR-mutated non–small-cell lung cancer LV Sequist, JC Soria, JW Goldman, HA Wakelee, SM Gadgeel, A Varga, ... New England Journal of Medicine 372 (18), 1700-1709, 2015 | 831 | 2015 |
| Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1) A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Cancer discovery 7 (4), 400-409, 2017 | 817 | 2017 |
| Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non–small-cell lung cancer AJ Weickhardt, B Scheier, JM Burke, G Gan, X Lu, PA Bunn Jr, DL Aisner, ... Journal of Thoracic Oncology 7 (12), 1807-1814, 2012 | 711 | 2012 |
| Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer A Vaishnavi, M Capelletti, AT Le, S Kako, M Butaney, D Ercan, S Mahale, ... Nature medicine 19 (11), 1469-1472, 2013 | 697 | 2013 |
| TRKing down an old oncogene in a new era of targeted therapy A Vaishnavi, AT Le, RC Doebele Cancer discovery 5 (1), 25-34, 2015 | 665* | 2015 |
| Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer KD Davies, AT Le, MF Theodoro, MC Skokan, DL Aisner, EM Berge, ... Clinical Cancer Research 18 (17), 4570-4579, 2012 | 543 | 2012 |
| Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers CM Blakely, TBK Watkins, W Wu, B Gini, JJ Chabon, CE McCoach, ... Nature genetics 49 (12), 1693-1704, 2017 | 500 | 2017 |
| Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing A Maynard, CE McCoach, JK Rotow, L Harris, F Haderk, DL Kerr, ... Cell 182 (5), 1232-1251. e22, 2020 | 468 | 2020 |
| Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer JP Robichaux, YY Elamin, Z Tan, BW Carter, S Zhang, S Liu, S Li, T Chen, ... Nature medicine 24 (5), 638-646, 2018 | 463 | 2018 |
| Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials A Drilon, S Siena, R Dziadziuszko, F Barlesi, MG Krebs, AT Shaw, ... The Lancet Oncology 21 (2), 261-270, 2020 | 450 | 2020 |
| Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC DR Camidge, RC Doebele, KM Kerr Nature reviews Clinical oncology 16 (6), 341-355, 2019 | 437 | 2019 |
| Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment DR Camidge, SA Kono, A Flacco, AC Tan, RC Doebele, Q Zhou, L Crino, ... Clinical Cancer Research 16 (22), 5581-5590, 2010 | 431 | 2010 |
Ross CamidgeVerified email at cuanschutz.edu
